Transthyretin Amyloidosis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Therapy, By Disease Type, By Distribution Channel, By Region & Competition, 2021-2031F

Description

The Global Transthyretin Amyloidosis Treatment Market is projected to expand significantly, rising from USD 7.78 Billion in 2025 to USD 17.82 Billion by 2031, reflecting a compound annual growth rate of 14.81%. This sector includes pharmacological treatments aimed at stabilizing the transthyretin protein or inhibiting its production in the liver to stop amyloid fibrils from accumulating in the heart and nerves. Growth is largely fueled by an aging global population and the widespread use of non-invasive nuclear scintigraphy, which has vastly improved diagnostic accuracy over older biopsy techniques. For instance, the European Society of Cardiology noted in 2025 that approximately 19% of elderly patients with unexplained hypertrophic cardiomyopathy were diagnosed with transthyretin amyloid cardiomyopathy, highlighting how targeted screening is revealing a larger patient base.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 7.78 Billion
Market Size 2031	USD 17.82 Billion
CAGR 2026-2031	14.81%
Fastest Growing Segment	Hospitals Pharmacy
Largest Market	North America

However, the market faces a major impediment due to the high costs associated with disease-modifying therapies, which create significant reimbursement obstacles and limit access within budget-constrained healthcare systems. These financial limitations frequently lead to delays in starting treatment or outright denial of insurance coverage, effectively curbing revenue growth even as the number of diagnosed cases continues to rise worldwide.

Market Driver

The primary engine for growth in the Global Transthyretin Amyloidosis Treatment Market is the introduction and increasing utilization of innovative disease-modifying therapies. Medical professionals are more frequently prescribing targeted treatments that either stabilize the transthyretin tetramer or suppress its hepatic synthesis, thereby modifying the disease's natural progression. This trend is highlighted by the strong commercial performance of existing standards of care and the rapid uptake of new products. For example, Pfizer Inc. reported in its Third Quarter 2024 Earnings that the Vyndaqel product family reached global revenues of USD 1.45 billion, representing 63 percent operational growth due to high demand. Additionally, AstraZeneca's Year to date and Q3 2024 Results in November 2024 indicated that its newly launched Wainua treatment generated USD 23 million in quarterly revenue, showing strong initial adoption in the polyneuropathy sector.

This commercial momentum is bolstered by a strong clinical pipeline and increased research and development investment aimed at broadening labeled indications and enhancing survival rates. Pharmaceutical companies are actively developing next-generation RNA interference and antisense oligonucleotide therapies to treat the larger cardiomyopathy patient group, which has historically been challenging to manage. A significant breakthrough occurred with the release of data confirming the effectiveness of gene silencers for cardiac issues; according to Alnylam Pharmaceuticals' June 2024 HELIOS-B Phase 3 Study Results, vutrisiran showed a statistically significant 28 percent reduction in the composite risk of all-cause mortality and recurrent cardiovascular events in patients with ATTR amyloidosis and cardiomyopathy. These advancements are essential for regulatory approvals that are expected to substantially expand the market size in the near future.

Market Challenge

A major barrier to market expansion is the exorbitant cost of disease-modifying therapies for transthyretin amyloidosis, which disrupts the link between improved diagnostic capabilities and revenue generation. Although screening programs are successfully identifying more patients, the steep prices of these lifelong medications force public and private insurers to implement strict reimbursement protocols. These financial hurdles often appear as complicated prior authorization processes or coverage refusals, preventing the growing pool of diagnosed patients from accessing treatment. As a result, manufacturers encounter a situation where clinical demand is increasing, yet actual product adoption is artificially constrained by economic gatekeeping.

The disconnect caused by financial toxicity directly affects patient access to care. Data from the Amyloidosis Research Consortium in 2024 revealed that one in five patients with transthyretin amyloidosis reported delaying treatment initiation specifically because of costs or insurance coverage difficulties. With a significant segment of the patient population compelled to postpone or forego therapy, affordability issues are directly shrinking the practical market size and hindering the sector's commercial trajectory.

Market Trends

The market is being fundamentally transformed by the advancement of In Vivo CRISPR-Cas9 gene editing therapeutics, which are shifting the treatment paradigm from chronic management to potential one-time curative solutions. Unlike current gene silencers that require ongoing administration, these next-generation agents use lipid nanoparticles to permanently disable the TTR gene in hepatocytes, effectively stopping the production of disease-causing proteins. The potential for a single dose to halt disease progression is supported by recent durability data; for instance, Intellia Therapeutics announced in its November 2024 Phase 1 Clinical Data that the investigational agent nexiguran ziclumeran achieved a deep and consistent mean serum TTR reduction of 90 percent at month 12 across all patients, irrespective of baseline levels.

Concurrently, the commercialization of next-generation high-affinity TTR stabilizers is setting a new benchmark for efficacy by achieving near-complete tetramer stabilization compared to earlier options. These novel small molecules are designed to maximize blood binding occupancy, thereby significantly lowering the release of toxic monomers responsible for amyloid deposition in the heart. This evolution toward superior stabilization was confirmed by recent regulatory achievements; according to BridgeBio Pharma's November 2024 announcement regarding the FDA approval for Attruby, data from the pivotal Phase 3 ATTRibute-CM trial demonstrated that acoramidis resulted in a 42 percent reduction in the composite risk of all-cause mortality and recurrent cardiovascular-related hospitalizations at month 30 compared to placebo.

Key Market Players

Alnylam Pharmaceuticals
Bridgebio Pharma
Pfizer
Ionis Pharmaceuticals
Astrazeneca
Alexion Pharmaceutical
Proliferan
Enobio Pharma
Moderna
Intellia Therapeutics
Regeneron Pharmaceuticals

Report Scope

In this report, the Global Transthyretin Amyloidosis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Transthyretin Amyloidosis Treatment Market, By Type

ATTR-PN
ATTR-CM

Transthyretin Amyloidosis Treatment Market, By Therapy

Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax)
Supportive Therapy
Pipeline Therapy

Transthyretin Amyloidosis Treatment Market, By Disease Type

Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type)
Wild Type Amyloidosis

Transthyretin Amyloidosis Treatment Market, By Distribution Channel

Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Online Pharmacies

Transthyretin Amyloidosis Treatment Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Transthyretin Amyloidosis Treatment Market.

Available Customizations:

Global Transthyretin Amyloidosis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Transthyretin Amyloidosis Treatment Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (ATTR-PN, ATTR-CM)
- 5.2.2. By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)
- 5.2.3. By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)
- 5.2.4. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)
- 5.2.5. By Region
- 5.2.6. By Company (2025)
5.3. Market Map

6. North America Transthyretin Amyloidosis Treatment Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Therapy
- 6.2.3. By Disease Type
- 6.2.4. By Distribution Channel
- 6.2.5. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Transthyretin Amyloidosis Treatment Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Therapy
    - 6.3.1.2.3. By Disease Type
    - 6.3.1.2.4. By Distribution Channel
- 6.3.2. Canada Transthyretin Amyloidosis Treatment Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Therapy
    - 6.3.2.2.3. By Disease Type
    - 6.3.2.2.4. By Distribution Channel
- 6.3.3. Mexico Transthyretin Amyloidosis Treatment Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Therapy
    - 6.3.3.2.3. By Disease Type
    - 6.3.3.2.4. By Distribution Channel

7. Europe Transthyretin Amyloidosis Treatment Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Therapy
- 7.2.3. By Disease Type
- 7.2.4. By Distribution Channel
- 7.2.5. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Transthyretin Amyloidosis Treatment Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Therapy
    - 7.3.1.2.3. By Disease Type
    - 7.3.1.2.4. By Distribution Channel
- 7.3.2. France Transthyretin Amyloidosis Treatment Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Therapy
    - 7.3.2.2.3. By Disease Type
    - 7.3.2.2.4. By Distribution Channel
- 7.3.3. United Kingdom Transthyretin Amyloidosis Treatment Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Therapy
    - 7.3.3.2.3. By Disease Type
    - 7.3.3.2.4. By Distribution Channel
- 7.3.4. Italy Transthyretin Amyloidosis Treatment Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Therapy
    - 7.3.4.2.3. By Disease Type
    - 7.3.4.2.4. By Distribution Channel
- 7.3.5. Spain Transthyretin Amyloidosis Treatment Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Therapy
    - 7.3.5.2.3. By Disease Type
    - 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Transthyretin Amyloidosis Treatment Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Therapy
- 8.2.3. By Disease Type
- 8.2.4. By Distribution Channel
- 8.2.5. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Transthyretin Amyloidosis Treatment Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Therapy
    - 8.3.1.2.3. By Disease Type
    - 8.3.1.2.4. By Distribution Channel
- 8.3.2. India Transthyretin Amyloidosis Treatment Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Therapy
    - 8.3.2.2.3. By Disease Type
    - 8.3.2.2.4. By Distribution Channel
- 8.3.3. Japan Transthyretin Amyloidosis Treatment Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Therapy
    - 8.3.3.2.3. By Disease Type
    - 8.3.3.2.4. By Distribution Channel
- 8.3.4. South Korea Transthyretin Amyloidosis Treatment Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Therapy
    - 8.3.4.2.3. By Disease Type
    - 8.3.4.2.4. By Distribution Channel
- 8.3.5. Australia Transthyretin Amyloidosis Treatment Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Therapy
    - 8.3.5.2.3. By Disease Type
    - 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Transthyretin Amyloidosis Treatment Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Therapy
- 9.2.3. By Disease Type
- 9.2.4. By Distribution Channel
- 9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Transthyretin Amyloidosis Treatment Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Therapy
    - 9.3.1.2.3. By Disease Type
    - 9.3.1.2.4. By Distribution Channel
- 9.3.2. UAE Transthyretin Amyloidosis Treatment Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Therapy
    - 9.3.2.2.3. By Disease Type
    - 9.3.2.2.4. By Distribution Channel
- 9.3.3. South Africa Transthyretin Amyloidosis Treatment Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Therapy
    - 9.3.3.2.3. By Disease Type
    - 9.3.3.2.4. By Distribution Channel

10. South America Transthyretin Amyloidosis Treatment Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Therapy
- 10.2.3. By Disease Type
- 10.2.4. By Distribution Channel
- 10.2.5. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Transthyretin Amyloidosis Treatment Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Therapy
    - 10.3.1.2.3. By Disease Type
    - 10.3.1.2.4. By Distribution Channel
- 10.3.2. Colombia Transthyretin Amyloidosis Treatment Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Therapy
    - 10.3.2.2.3. By Disease Type
    - 10.3.2.2.4. By Distribution Channel
- 10.3.3. Argentina Transthyretin Amyloidosis Treatment Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Therapy
    - 10.3.3.2.3. By Disease Type
    - 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Transthyretin Amyloidosis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Alnylam Pharmaceuticals
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Bridgebio Pharma
15.3. Pfizer
15.4. Ionis Pharmaceuticals
15.5. Astrazeneca
15.6. Alexion Pharmaceutical
15.7. Proliferan
15.8. Enobio Pharma
15.9. Moderna
15.10. Intellia Therapeutics
15.11. Regeneron Pharmaceuticals